

Implementation Guide

CMS's Million Hearts® Model Longitudinal ASCVD Risk Assessment Tool for Baseline 10- Year ASCVD Risk

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
5600 Fishers Lane
Rockville, MD 20857
www.ahrq.gov

Contract No. HHS A290201600001U

Prepared by:

Pace Ricciardelli, MS
Sharon Sebastian, MS, RN-BC, PMP, CPHIMS
Jonathan Teich, MD, PhD
MITRE Corporation

AHRQ Publication No. 18-0007-1-EF

February 2018

Disclaimer

The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

Disclaimer of Conflict of Interest

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

Funding Statement

This project was funded under contract/grant number HHS290201600001U from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services. The opinions expressed in this document are those of the authors and do not reflect the official position of AHRQ or the U.S. Department of Health and Human Services.

Public Domain Notice

This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated.

Suggested Citation

Suggested citation: Ricciardelli P, Sebastian S, Teich, J. Implementation Guide: Longitudinal ASCVD Risk Assessment Tool for Baseline 10-Year ASCVD Risk. Prepared under Contract No. HHS290201600001U. AHRQ Publication No. **18-0007-1-EF**. Rockville, MD: Agency for Healthcare Research and Quality; October 2017.

Contents

Introduction	1
Background	1
Audience, Purpose, and Scope of this Implementation Guide.....	1
Implementing and Using This Artifact.....	2
Description and Purpose of the Artifact.....	2
Summary of the Clinical Statement	2
Primary Use Cases	3
Additional Use Cases	5
Recommendations and Suggested Actions	6
Guideline Interpretation and Clinical Decisions	6
Artifact Manifest.....	7
Artifact Relationship Diagram	8
Testing.....	9
Implementation Checklist.....	9
Potential Reuse Scenarios	11
General Information About CQL	11
Appendix A: Decision Log	12
Artifact Recommendation Statements	13
Decision Logs	13
Appendix B: Test Data	17
Appendix C: Acronyms.....	19
Reference List	20
Figures	
Figure 1: ASCVD Risk Calculator Example	4
Figure 2: Artifact Relationship Diagram	9
Figure 3: CDS Artifact Maturity Process.....	10

Tables

Table 1: Artifact Manifest.....	7
Table 2: Definitions of Shiffman's Steps	12
Table 3: Decisions Based on "Atomized" Components of the Recommendation Statement	13
Table 4: Additional Decisions	14
Table 5: Basic Tests	17
Table 6: Missing or Old Data Tests	18

Introduction

The Agency for Healthcare Research and Quality (AHRQ) has elected to sponsor a project that will help to generate a systematic and replicable process for transforming patient-centered outcomes research (PCOR) findings into shareable and standards-based clinical decision support (CDS) artifacts. A CDS artifact is the template for defining how decision support is provided for a given clinical situation, often including triggers, logic, operations, recommendations and actions, and supporting evidence. A main outcome of this project will be an online Repository for storing and accessing CDS artifacts. It is hoped that this publicly available Repository will promote the usage of CDS in everyday clinical settings, and that it will serve as the cornerstone for connecting high-quality CDS to the U.S. healthcare community.

Background

The purpose of the CDS Connect Repository is to store and provide access to CDS artifacts, including text and computable versions of the decision logic; suggested trigger events; text recommendations and suggested actions; and metadata, including original evidence links, decisions made while creating the artifact, sponsoring clinical organizations, and keywords. It is envisioned that it may at some point become a home for user feedback and experience data as well. The CDS Connect Repository enables users to search easily for desired artifacts to explore their contents, and to facilitate their transfer into and use in locally used electronic health records (EHRs), CDS services, and other technology tools.

The concept of a CDS Repository was introduced in the HHS-sponsored Roadmap for National Action on Clinical Decision Support¹ (2006). Subsequent efforts, including the CDS Consortium (2008), Advancing CDS contract (2010), National Quality Forum CDS Expert Panel (2011), Health eDecisions (2012), and the National Academy of Medicine Optimizing Strategies for CDS project, among others, have advanced the concept of shared CDS. The CDS Connect project advances the goal of shareable CDS by establishing an actual public repository of CDS that can be contributed to and consumed by many stakeholders.

With further development, additional features are projected for the Repository, including—

- making several types of CDS available (such as alerts, order sets, intelligent data presentations, relevant evidence and knowledge; tools for shared decision-making with patients).
- providing several options for displaying and using Repository information.
- allowing users to subscribe to artifact updates.
- allowing users to review and rate artifacts in the Repository and provide usage data.

These features will enhance the quality, validity, and value of the Repository, and create a climate of mutual ownership of artifacts across the CDS and EHR user community. The provenance and sponsorship of any artifact is visible and searchable in the Repository.

Audience, Purpose, and Scope of this Implementation Guide

This document is intended to provide information about the generation, implementation, and routine operation of the Longitudinal ASCVD Risk Assessment Tool for Baseline 10-Year ASCVD Risk artifact. Various audiences may find this information helpful, including:

1. **Clinicians and Quality Leaders** at healthcare organizations and practices who wish to implement, test, and execute CDS related to this topic in their EHRs and other health information tools.
2. **Patients and Family Caregivers** who wish to have active CDS to help them direct self-care activities or who are interested in the process of CDS development and implementation for shared decision-making more generally.
3. **CDS Developers and Informaticists** who may have suggestions, additions, or seek to add CDS artifacts on similar topics, or who want to make use of well-developed structured logic and Clinical Quality Language (CQL) in their own work.
4. **Organizations or Individuals** interested in developing their own CDS artifacts, who may find this document helpful as a guideline for the process by which clinical guidelines are translated into mature CQL artifacts.

Implementing and Using This Artifact

Description and Purpose of the Artifact

This artifact provides the ability to calculate and display the base 10-Year ASCVD risk score for an individual to help in considering initiation or optimization of therapy for primary prevention of ASCVD. It utilizes the 2013 ACC/AHA pooled cohort equation to calculate the risk for developing a first-time “hard” ASCVD event, defined as: nonfatal myocardial infarction (MI), coronary heart disease (CHD) death, nonfatal stroke, or fatal stroke.

This artifact addresses the first of 3 clinical scenarios where the Longitudinal ASCVD Risk Assessment Tool might be used:

1. **Calculation of a baseline 10-Year ASCVD risk assessment score, prior to initiation of any new therapies to address this risk.**
2. Prospective estimations of ASCVD risk in support of shared decision making while considering the benefits of therapies, alone or in combination.
3. Calculation of updated risk after preventive therapies have been initiated.

Summary of the Clinical Statement

The basis of the risk calculator comes from the 2017 ACC/AHA Special Report². The Million Hearts® Model Longitudinal ASCVD Risk Assessment Tool is an instrument that uses the ACC/AHA 2013 Pooled Cohort Equations (PCE), providing sex- and race-specific 10-year estimates of ASCVD risk. It is intended for use in patients 40-79 years of age who have not had ASCVD. The risk calculation has been validated in a broadly representative sample of U.S. whites and African Americans.

The Baseline calculation allows for estimate of initial baseline risk based on key parameters, including age, gender, race, total and HDL cholesterol, systolic blood pressure, smoking within the past year, presence of diabetes, and treatment for high blood pressure.

The Shared Decision-Making calculation shows the change in estimated risk associated with institution of one or more preventive interventions, including smoking cessation, aspirin therapy, blood pressure control, and statin therapy, if these have not already been started.

The Updated calculation provides the ability to compare the original Baseline risk with the Updated risk based on interventions that have been instituted and their impact on measures including LDL cholesterol and systolic blood pressure.


Additional reference information can be found in the Textual Metadata section of the artifact in the CDS Connect Repository.

Primary Use Cases

The three ASCVD risk calculations in this artifact family are primarily for use by providers and patients doing assessment and treatment planning in a primary care or cardiology practice setting. The artifact is suitable for producing an intelligent data display. An implementation of the CDS artifact can produce (1) a “calculator” view of the parameters listed above, with opportunity for the user to correct or adjust any values, and (2) the calculated risk score, displayed on screen, and also potentially available for other CDS artifacts, such as cholesterol-lowering CDS algorithms that make use of the risk score as part of their calculation.

A typical calculator view might look like Figure 1, where the score is prominently displayed while the supporting parameters, whether filled in automatically from EHR data or adjusted manually, appear below.

Figure 1: ASCVD Risk Calculator Example



The baseline risk is calculated for patients between the ages of 40-79 without ASCVD.

Typical scenarios include:

1. Upon request, typically as part of a patient encounter

Ms. Bravo, a 55-year-old African-American nondiabetic patient with hypertension, comes in for a regular annual checkup. She has not had an ASCVD risk calculation done previously. Her clinical practitioner requests the risk calculator to execute. Using data from Ms. Bravo’s EHR, the algorithm executes and a data view or calculator view is displayed on

screen, showing all of the relevant parameters and her calculated risk score of 10.9%. In some implementations, this view also allows manual adjustment of parameters that might not have been fully or correctly captured, such as smoking status.

2. Any time that the patient’s record is opened by a clinician’s direct action

Dr. Alfa is going through the records of his patients to be seen this afternoon, and is currently reviewing the record of Ms. Bravo, a scheduled patient. When the record is opened in the EHR, CDS logic could trigger if the patient is of the appropriate age and has not had a prior ASCVD risk calculation. The risk score is displayed on the patient’s chart, and the calculator can be brought up with a manual request.

3. As part of another CDS artifact

A CDS artifact to consider whether to recommend a statin is being run on Mr. Delta. This artifact requires the risk score to be known as part of its logic. In some systems, that artifact can invoke this one as a subtask. Dr. Charlie is notified that the statin artifact requires this logic in support, and can approve its execution and work through its user interface. It is also possible for this artifact to run unattended, but there are more caveats about missing data (refer to “Additional Use Cases”).

Additional Use Cases

Additional use cases make use of the decision logic and recommendations, but may require adjustments for a different workflow, type of user, or mode of operation. Additional use cases for this artifact could include:

1. As automatic surveillance run at a fixed time the night before the practice opens each day

Dr. Charlie’s practice automatically runs a review each evening on all patients to be seen the following day. This review sets up face-sheets and requests charts for the intake personnel to use the next day. As part of this review, the computer scans each patient for several health maintenance gaps, including using this CDS artifact to identify patients with elevated risk scores. Since this runs in bulk, it is not usually possible to have a direct user interface to modify individual patient parameters. Thus, the artifact could record an exception if the necessary parameters do not exist, or it could assume worst case of parameters that are not already captured in the EHR or other health IT tool. In this use case, the artifact posts a message in the Inbox of the provider or quality manager, or a To-Do item on the chart for each patient whose risk score is above a certain threshold. The recommendation can also be printed as part of the patient’s visit face-sheet. The logic to determine which parameters are required and what minimum risk score should be called out for this automated operation is beyond the scope of this implementation guide.

2. Population health: Inclusion in a requested or periodic screening scan of an entire patient panel or population.

Dr. Charlie’s practice is running a quarterly quality screen to find patients in need of various health maintenance and promotion services. The ASCVD risk artifact is run as a report for all patients in the practice. Recommendations and suggested actions (RSAs) for appropriate patients appear on each patient’s individual To-Do list, and are also compiled

into an overall report that can be addressed by population health or case management workers. The additional considerations for unattended bulk operation noted above also apply to this use case.

3. Patient self-care/family caregivers as part of self-assessment or health maintenance:

Mr. Delta runs an overall general health self-assessment or cardiac risk self-screen as part of a self-care program. The risk score display is presented immediately with the assessment results, or can be delivered as a secure message to the patient on a self-care website. The former is preferred because it allows adjustment of parameters, and allows the self-assessment tool to chain to other CDS based on the risk score.

Recommendations and Suggested Actions

The recommendations, warnings, and interventions provided by this CDS artifact can be found in detail under **“Potential Intervention(s) and Action(s)” in the Semi-Structured Representation section of the artifact**. In summary, they include:

1. Notify the user if the patient is excluded, because of age less than 40 or greater than 79.
2. Notify the user that, although the algorithm is executing, it may not be fully valid or may need to be adjusted for patients with familial hypercholesterolemia, or patients who are not white or African-American.
3. Display the ASCVD risk calculation as a calculator view or data view.
4. Fill in known parameters to this calculation from EHR data, while indicating which parameters could not be obtained, if any.
5. Notify the user that certain parameters (including total cholesterol, HDL cholesterol, and systolic blood pressure) were out of the validated range and have been adjusted to the nearest in-range value.
6. Display the ASCVD risk score as derived from the collected and entered parameters.
7. Document the ASCVD risk score in the patient’s record. This is not a standard EHR data element, and currently each implementation needs to identify where this is stored in the record for applications that make use of the score and for documenting that a score was performed.

Guideline Interpretation and Clinical Decisions

It is often necessary to interpret or adjust clinical guidelines to make them suitable for computation. In addition, the CDS Connect Cholesterol Management Work Group provided insight to clarify exclusions, inclusions, and parameters that were specified in the guideline statement, outlined in the original reference describing the guideline, or deemed to be otherwise important to the proper application of the guideline as CDS. Decisions outlined in Appendix A explain, in detail, how source content text was interpreted and representations were defined during artifact creation.

Some of the more meaningful interpretations and decisions found in Appendix A include:

1. Maintain a modular approach to CDS creation by separating the calculation of ASCVD risk (in this artifact) from statin therapy recommendations presented in other artifacts. These artifacts will be tagged as being related to each other, but allow the user options in what is implemented.

2. Indicate that non-white, non-African-American patients may need score adjustment, but still provide the risk calculation as specified.
3. Replace values for systolic hypertension, HDL cholesterol, and total cholesterol that are outside the validated ranges for this algorithm with the nearest in-range value and proceed with the calculation, but notify the user that this adjustment was made.
4. At present, the CQL code does not evaluate for evidence of ASCVD in the patient record since this artifact is a representation of the risk assessment equation alone, as opposed to a more comprehensive CDS expression. Future implementers may choose to represent ASCVD as an exclusion based on their needs.
5. Define “treatment for hypertension” as the existence of an active antihypertensive medication in the patient’s file and a diagnosis of hypertension, since several antihypertensive medications are used for other indications.
6. Limit data evaluation to concepts required to calculate a baseline 10-year ASCVD risk score. Future implementers may choose to evaluate and track a “baseline” low-density lipoprotein (LDL) value, or treatment with statin therapy or aspirin therapy prior to changing or initiating therapy. At present, these concepts are not expressed in the CQL code.
7. CQL code alignment with the precision implemented in the Million Hearts® Model Longitudinal ASCVD Risk Assessment Tool and online calculators, as opposed to the 2013 Report on the Assessment of Cardiovascular Risk: Full Work Group Report Supplement (which calculates risk scores that may be off as much as 0.001).
8. CQL code does not evaluate ethnicity or a history of familial hypercholesterolemia. End users should be aware that these factors can impact the accuracy of the calculated score. This information is listed in the “Caution” Repository metadata.

Artifact Manifest

CMS’s Million Hearts® Model Longitudinal ASCVD Risk Assessment Tool for Baseline 10-Year ASCVD Risk artifact is comprised of eight distinct files listed in **Table 1** (below).


Table 1: Artifact Manifest

Filename	Purpose	Author(s)
Million_Hearts_Baseline_10_Year_ASCVD_Risk_FHIRv102.cql	CQL representation of CMS’s Million Hearts Model Longitudinal ASCVD Risk Assessment Tool for baseline 10-year ASCVD Risk. The CQL provides the ability to calculate the base 10-year ASCVD risk score for an individual that is not receiving therapy for primary prevention of ASCVD. It utilizes the 2013 ACC/AHA pooled cohort equation to calculate the risk of developing a first time “hard” ASCVD event, defined as: nonfatal myocardial infarction (MI), coronary heart disease (CHD) death, nonfatal stroke, or fatal stroke.	Rute Martins, Chris Moesel, Sharon Sebastian

Filename	Purpose	Author(s)
Million_Hearts_Baseline_10_Year_ASCVD_Risk_FHIRv102.json	JSON representation of CMS's Million Hearts Model Longitudinal ASCVD Risk Assessment Tool for baseline 10-year ASCVD Risk. The CQL provides the ability to calculate the base 10-year ASCVD risk score for an individual that is not receiving therapy for primary prevention of ASCVD. It utilizes the 2013 ACC/AHA pooled cohort equation to calculate the risk of developing a first time "hard" ASCVD event, defined as: nonfatal myocardial infarction (MI), coronary heart disease (CHD) death, nonfatal stroke, or fatal stroke.	Rute Martins, Chris Moesel, Sharon Sebastian
CDS_Connect_Commons_for_FHIRv102.cql	Common CQL functions that may be called by CDS Connect artifacts.	Rute Martins, Chris Moesel, Sharon Sebastian
CDS_Connect_Commons_for_FHIRv102.json	JSON representation of common CQL functions that may be called by CDS Connect artifacts.	Rute Martins, Chris Moesel, Sharon Sebastian
CDS_Connect_Conversions.cql	A library that supports conversions from one unit to another.	Rute Martins, Chris Moesel, Sharon Sebastian
CDS_Connect_Conversions.json	JSON representation of a library that supports conversions from one unit to another.	Rute Martins, Chris Moesel, Sharon Sebastian
FHIRHelpers.cql	Common CQL functions used to convert CQL data elements to FHIR and back again.	Rute Martins, Chris Moesel, Sharon Sebastian
FHIRHelpers.json	JSON representation of common CQL functions used to convert CQL data elements to FHIR and back again.	Rute Martins, Chris Moesel, Sharon Sebastian

Artifact Relationship Diagram

CQL developers are encouraged to refactor commonly used functions into their own files. The diagram in Figure 2 shows the relationships between the files included in this artifact (as described above). In this case, the Million_Hearts_Baseline_10_Year_ASCVD_Risk_FHIRv102 file includes several libraries. When implementing this artifact, please ensure that all files are present and the filenames have not been modified.

Figure 2: Artifact Relationship Diagram

Testing

CMS’s Million Hearts® Model Longitudinal ASCVD Risk Assessment Tool for Baseline 10-year ASCVD Risk artifact was tested using an automated testing framework written in Node.js. This framework accepted test cases in a .csv (comma-separated value) file, executed the artifact against each test case, and reported the success or failure of each test case. Test cases were developed to investigate efficacy for basic expected functionality and to test the expected inclusion criteria. A selection of the test data used for this artifact is included in Appendix B. In addition, test data provided by the ACC/AHA were used to further test the expressed equation. The ACC/AHA test data are available at: *Final Technical Report: Estimating Benefits in Risk Reduction from Cardiovascular Preventive Therapies in Medicare Patients: Development of the Longitudinal ASCVD Risk Estimator*. Implementers should review their organizational priorities and develop a similar testing framework (and test cases) prior to implementation in a production system.

Implementation Checklist

Boxwala et al.³ developed a multi-layered knowledge representation framework for structuring guideline recommendations as they are transformed into CDS artifacts. The framework defines four “layers” of representation:

1. **Narrative** text created by a guideline or clinical quality measurement (CQM) developer (e.g., the recommendation statement described as a sentence).
2. **Semi-structured** text that describes the recommendations for implementation as CDS, often created by clinical subject matter experts. It serves as a common understanding of the clinical intent as the artifact is translated in to a fully structured format by software engineers.
3. **Structured** code that is interpretable by a computer and includes data elements, value sets, and coded logic.

4. **Executable** code that is interpretable by a CDS system at a local level. This code will vary for each site.

This artifact is a **structured** representation of medical knowledge that contains code files that represent the source content (e.g., recommendation statement).

Figure 3: CDS Artifact Maturity Process



Prior to incorporating this artifact in a production setting, implementers should consider the following items:

- Analyze the purpose, clinical statement, and use case sections of this document to ensure that your organization understands and agrees with the intended goals of the clinical guideline on which this artifact is based.
- Review the “clinical considerations” section of this document (including the cited decision log) to ensure that your organization understands and agrees with the decisions made during the process to convert the underlying clinical guideline to a structured, computable CDS artifact.
- Technical staff should read through each of the files in the artifact manifest to understand their respective purposes and how they can be successfully incorporated into a clinical information technology (IT) system. At the time of publication, many commercial off-the-shelf (COTS) EHR systems are unable to use CQL files natively and require a separate application to convert CQL code such that it can be used in those EHR systems. Implementers should work with vendors of their respective health IT products to understand their readiness to implement CQL code and any potential adverse impacts to existing functionality. In a pilot setting, developers have worked around existing EHR limitations by implementing a web service wrapper around a CQL execution engine. This is a non-trivial amount of work with two primary components:
 - a CQL execution engine with a RESTful web service designed to accept requests for CQL execution and to respond with the calculated results, and
 - modifications to the EHR system such that it will
 - trigger RESTful events to call the CQL execution engine,
 - interpret the response,
 - and reflect the CQL-generated recommendations and suggested actions in the EHR user interface.
- After incorporation into a development environment, the artifact should be exhaustively tested against predefined test cases. Additionally, testing should be conducted to ensure that implementation of the artifact has no adverse effect on the processing efficiency of the health IT system.
- Documentation and training materials for clinical staff should be drafted and distributed. These training materials should include descriptions of modified functionality, directions for interacting with CDS rules (if different than in the current system), and contact information for assistance if functionality does not meet expectations.

Potential Reuse Scenarios

CQL code within this artifact was developed to enact an ASCVD risk calculation, but there are portions of the CQL code that are expected to be useful for other purposes.

- The CDS_Connect_Commons_for_FHIRv102, FHIRHelpers, and CDS_Connect_Conversions libraries included in the artifact define commonly used functions in CQL files and are not specific to this artifact. They are expected to be used with any other CQL file that could benefit from those functions.
- Selected code blocks from Million_Hearts_Baseline_10_Year_ASCVD_Risk_FHIRv102 could be copied and reused in other CQL files. For example, the expanded CMS Million Hearts Model Longitudinal ASCVD Risk Tool, which facilitates calculation of an updated ASCVD risk score after treatment has been initiated.

General Information About CQL

The USPSTF Statin Use for the Primary Prevention of CVD in Adults artifact is composed of several files, but the primary focus of the artifact is the introduction of CQL files that can be used by any health care organization to properly identify populations of patients that require a specific message or clinical intervention. CQL is a data standard governed by Health Level 7[®] (HL7) that is currently a standard for trial use (STU). CQL expresses logic in a human-readable document that is also structured enough for electronic processing of a query. It can be used within both the CDS and CQM domains.

If you would like to learn more about CQL, there are a few resources (care of the [eCQI Resource Center](#)) that you should review:

- [CQL STU Release 1 at HL7](#)
- [CQL Tools on GitHub](#)
- [CQL Formatting and Usage Wiki](#)
- [CQL Online](#)

CQL Q&As on the eCQI Resource Center

Appendix A: Decision Log

The decision log was generated per procedures published by Tso et al.,⁴ which incorporates and extends steps that Shiffman et al.⁵ outlined for translating clinical practice guidelines to CDS. Brief descriptions of the steps in this process are included in the following table:

Table 2: Definitions of Shiffman's Steps

Decision Category	Definition
Select Guidelines	Choosing specific guidelines and specific recommendations within the selected guidelines to be implemented
Markup	Identifying and tagging guideline knowledge components relevant to operationalization
Atomize	The process of extracting and refining single concepts from the narrative text recommendations
Deabstract	The process of adjusting the level of generality at which a decision variable or action is described to permit operationalization
Disambiguate	The process of establishing a single semantic interpretation for a recommendation statement
Build Executable Statements	Arranging the atomized, de-abstracted, and disambiguated decision variables and actions into logical statements that can be translated readily into computable statements
Verify Completeness	The process of making sure that each recommendation provides guidance in all situations that a clinician is likely to face
Add Explanation	A facility to describe the reasoning behind recommendations
Identify Origin	Identifying a source or origin in the clinical environment for each decision variable
Insert Recommendations	Identifying an insertion point in the care process for each recommended action
Define Action Type	Categorizing guideline-recommended activities per predefined action types
Define Associated Beneficial Services	Linking action types to associated beneficial services that offer design patterns for facilitating clinical care
Design User Interface	Selecting and grouping user interface elements to best deliver CDS output

Artifact Recommendation Statements

ACC/AHA Recommendation Statement

The race- and sex-specific PCE to predict 10-year risk of a first hard ASCVD event should be used in non-Hispanic African Americans and non-Hispanic whites, 40–79 years of age.

Decision Logs

Table 3: Decisions Based on "Atomized" Components of the Recommendation Statement

Recommendation Statement	"Atomized" Word or Phrase	Interpretation
ACC/AHA	"race"	Per ACC/AHA guidelines: African American or White
ACC/AHA	"sex"	Per ACC/AHA guidelines: Male or Female
ACC/AHA	"pooled cohort equations"	Provides race- and sex-specific 10-year ASCVD risk calculations for African American and white men and women between 40-79 years of age
ACC/AHA	"predict"	Determine the likelihood of occurring
ACC/AHA	"10-year risk"	Risk of showing evidence of ASCVD within the next 10 years
ACC/AHA	"hard"	Nonfatal MI, CHD death, nonfatal stroke, or fatal stroke
ACC/AHA	"ASCVD"	Arteriosclerotic cardiovascular disease. For the purposes of this artifact, ASCVD is represented by a grouped value set that represents an array of conditions and procedures that would only occur if a patient has CVD. High level concepts include: "Diagnosis: "Ischemic Vascular Disease" "Diagnosis: Myocardial Infarction" "Procedure, Performed: CABG Surgeries" "Procedure, Performed: PCI" "Procedure, Performed: Carotid Intervention"
ACC/AHA	"non-Hispanic"	Individual does not report as being of Hispanic ethnicity
ACC/AHA	"40-79 years"	>=40 years of age and <=79 years of age

Several decisions were made outside the scope of the atomized words and phrases in the recommendation statements. These additional decisions were made based on the best available clinical knowledge and were encountered at various stages in the artifact development process.

Table 4: Additional Decisions

Decision Category	Concept	Rationale
Reconcile multiple guidelines	Presence of CVD risk factors as a requirement to calculate 10-year risk	The U.S. Preventive Services Task Force (USPSTF) guidelines recommend the calculation of 10-year risk only in the presence of 1 or more risk factors (e.g., smoking, hypertension), whereas the ACC/AHA guidelines do not require the presence of a risk factor. Based on Cholesterol Management Work Group feedback and to more closely align with the ACC/AHA Special Report, risk factors were not added to inclusion logic. Local implementers can add these specifications if desired, based on their organization's policy and practice.
Implementation guidance	Use of the Longitudinal ASCVD Tool (i.e., PCE) on Hispanic individuals	The Cholesterol Management Work Group felt the benefit of calculating ASCVD risk for Hispanic individuals using the PCE outweighs the chance that it may slightly over- or underestimate ASCVD risk, and providers can and should use their judgement on how the risk score might be adjusted for each unique individual. Consider adding a notification that caveats the risk score if the patient is Hispanic during structured specification of this artifact.
Implementation guidance	Age specification in the Inclusion logic	The ACC/AHA recommends 10-year ASCVD risk assessment for eligible 40-79-year-old individuals every 4-6 years, which is specified in the CDS logic. Upper and lower age parameters can be changed during implementation if a risk score is needed for an individual outside this age range. Refer to the ACC/AHA Special Report and ACC/AHA Guideline on the Assessment of Risk for additional information.
Implementation guidance	History of ASCVD	The PCE calculates the risk of developing ASCVD within the coming 10 years. If an individual already has ASCVD, use of the calculator is not indicated. At present, the CQL code does not evaluate for evidence of ASCVD in the patient record since this artifact is a representation of the risk assessment equation alone, as opposed to a more comprehensive CDS expression. Future implementers may choose to represent ASCVD as an exclusion based on their needs.
Implementation guidance	History of Familial Hypercholesterolemia (FH)	Based on Cholesterol Management Work Group feedback, individuals with a history of FH should not be excluded from a risk score calculation (because the PCE underestimates risk in these individuals). The score is valuable information that can guide care. At present, the CQL code does not caveat the calculated score if a patient has a history of FH. Implementers may choose to add this capability in the future.

Decision Category	Concept	Rationale
Verify completeness of logic and add explanation	Facilitate calculation of ASCVD risk, when possible	<p>The Longitudinal Tool includes parameters for several values (e.g., minimum and maximum systolic blood pressure [SBP] and lab values). If patient data is outside the defined range, a score will not calculate. In this scenario:</p> <ul style="list-style-type: none"> - CDS logic will replace the value with the nearest "allowable" value so the ASCVD score can be calculated. - the score is caveated. - the provider is notified of the replacement (e.g., true SBP value = 212, SBP value used for calculation = 200). <p>Per the Cholesterol Management Work Group, it is far more important to know the approximated risk score than to have no score on which to base decisions.</p>
Deabstract	Logic definition of "Diabetes" for data input to risk equation	Diabetes is defined as Type 1 and Type 2 based on text in the ACC/AHA guidelines. The presence of a Type 1 or Type 2 Diabetes SNOMED-CT or ICD code will translate as "Y" for the calculation.
Disambiguate	Logic definition of "Treated for Hypertension" for data input to risk equation	Per the Cholesterol Management Work Group, the presence of an anti-hypertensive medication in the patient record is not sufficient evidence that the patient is being treated for hypertension, since some anti-hypertensive medications can be prescribed for other medical conditions. To evaluate positively as being treated for hypertension, the patient must have a diagnosis of hypertension <i>and</i> evidence that they are being treated for hypertension (e.g., an appropriate medication order).
Verify completeness of logic	MOST RECENT for lab and SBP values and smoking status to ensure clinical relevance	The most recent values are most reflective of the patient's current condition. Use of the MOST RECENT values assumes that they were recorded using best practices (i.e., if highly abnormal or unreasonable the results would be completed; therefore, the MOST RECENT result indicates a valid result).
Verify completeness of logic	Lookback of 6 years for lab values and SBP value and a lookback of 1 year for smoking status to ensure clinical relevance	The ACC/AHA recommends assessment of ASCVD risk every 4-6 years. Results older than 6 years may not accurately reflect the individual's current condition. Since lipid profile results, SBP, are inputs to ASCVD risk assessment, a 6-year lookback supports a calculation that will most accurately reflect risk. In addition, the ACC/AHA specifies "current smoker" (i.e., within the past year), since the impact that smoking has on the body and ASCVD risk changes after that period. If the most recent result of any of these items is greater than the designated lookback period, a notification warning or error will be presented to the provider to provide awareness and prompt updates.

Decision Category	Concept	Rationale
Implementation guidance	Precision of risk score calculation	The CQL code in this artifact aligns with the more precise calculations implemented in the Million Hearts® Model Longitudinal ASCVD Risk Assessment Tool and online calculators, as opposed to the 2013 Report on the Assessment of Cardiovascular Risk: Full Work Group Report Supplement. In addition, discrepancies were noted in the test data included in the 2013 Report (i.e. copy/paste errors and incorrect rounding, which can lead to results that are off by as much as 0.001).
Implementation guidance	“LDL”, “Statin Therapy” and “Aspirin Therapy”	The concepts of LDL, statin therapy, and aspirin therapy are not required or evaluated against to determine baseline ASCVD risk, therefore they are not expressed in the CQL code. Future implementers may choose to evaluate and track a “baseline” low-density lipoprotein (LDL) value, or treatment with statin therapy or aspirin therapy prior to changing or initiating therapy by adding to the CQL specifications.

Appendix B: Test Data

In conjunction with a custom Node.js testing framework, the following data tables were used to test CMS's Million Hearts® Model Longitudinal ASCVD Risk Assessment Tool for Baseline 10-Year ASCVD Risk artifact:

Table 5: Basic Tests

TestCase	Patient	age	race	TotalCholesterol	valueQuantityCode	HDL	valueQuantityCode	SystolicBP	SmokingStatus	Diabetes	Hypertension	AntiHypertensiveOrder	RESULT: InDemographic	RESULT: ErrorsAndWarnings	RESULT: PatientBaselineRisk
Table A White Women	female	55	white	213		50		120	never				TRUE	<empty>	0.02050996
Table A African American Women	female	55	black	213		50		120	never				TRUE	<empty>	0.02992591
Table A White Men	male	55	white	213		50		120	never				TRUE	<empty>	0.05386982
Table A African American Men	male	55	black	213		50		120	never				TRUE	<empty>	0.06075817
Healthy Patient	male	47	white	187		58		107	never				TRUE	<empty>	0.01399841
At Risk Patient	female	42	black	215		37		143	current	+	+	+	TRUE	<empty>	0.32241902
Cholesterol in mmol/L	male	47	white	4.835820031	mmol/L	1.49988001	mmol/L	107	never				TRUE	<empty>	0.01399841
Off-label Med	male	47	white	187		58		107	never			+	TRUE	<empty>	0.01399841
Above Total Cholesterol Range	male	47	white	350		58		107	never				TRUE	~WARNING: Total cholesterol 350 mg/dL	0.032685
Below Total Cholesterol Range	male	47	white	120		58		107	never				TRUE	~WARNING: Total cholesterol 120 mg/dL	0.00785933
Above HDL Range	male	47	white	250		120		107	never				TRUE	~WARNING: HDL 120 mg/dL	0.01171975
Below HDL Range	male	47	white	150		15		107	never				TRUE	~WARNING: HDL 15 mg/dL	0.03419587
Above Systolic BP Range	male	47	white	187		58		220	never				TRUE	~WARNING: Systolic blood pressure 220 mmHg	0.04160308
Below Systolic BP Range	male	47	white	187		58		70	never				TRUE	~WARNING: Systolic blood pressure 70 mmHg	0.01033553
Other Race	male	47	asian	187		58		107	never				TRUE	~For non-White and non-African American ethnic groups	0.01399841
Other Gender	other	47	white	187		58		107	never				TRUE	~ERROR: Inadequate data to process CDS: gender	<null>
Too Old	male	80	white	187		58		107	never				FALSE	~ERROR: This CDS is not applicable	<null>
Too Young	male	39	white	187		58		107	never				FALSE	~ERROR: This CDS is not applicable	<null>

Table 6: Missing or Old Data Tests

TestCase	Patient	age	race	TotalCholesterol	issued	HDL	issued	SystolicBP	issued	SmokingStatus	issued	RESULT: InDemographic	RESULT: ErrorsAndWarnings	RESULT: PatientBaselineRisk
Missing gender	+	47	white	187		58		107		never		TRUE	~ERROR: Inadequate data to process CDS: gender	<null>
Missing birthdate	male		white	187		58		107		never		<null>	~ERROR: Inadequate data to process CDS: birthdate	<null>
Missing race	male	47		187		58		107		never		TRUE	~ERROR: Inadequate data to process CDS: race	<null>
Missing Total Cholesterol	male	47	white			58		107		never		TRUE	~ERROR: Inadequate data to process CDS: total cholesterol	<null>
Old Total Cholesterol	male	47	white	187	1/1/12	58		107		never		TRUE	~ERROR: Inadequate data to process CDS: total cholesterol	<null>
Missing HDL	male	47	white	187				107		never		TRUE	~ERROR: Inadequate data to process CDS: HDL	<null>
Old HDL	male	47	white	187		58	1/1/12	107		never		TRUE	~ERROR: Inadequate data to process CDS: HDL	<null>
Missing Systolic BP	male	47	white	187		58				never		TRUE	~ERROR: Inadequate data to process CDS: systolic blood pressure	<null>
Old Systolic BP	male	47	white	187		58		107	1/1/12	never		TRUE	~ERROR: Inadequate data to process CDS: systolic blood pressure	<null>
Missing Smoking Status	male	47	white	187		58		107				TRUE	~ERROR: Inadequate data to process CDS: smoking status	<null>
Old Smoking Status	male	47	white	187		58		107		never	1/1/12	TRUE	~ERROR: Inadequate data to process CDS: smoking status	<null>

Appendix C: Acronyms

Acronym	Full Name
ACA	Affordable Care Act
AHRQ	Agency for Healthcare Research and Quality
CAMH	CMS Alliance to Modernize Healthcare
CDS	Clinical Decision Support
CMS	Centers for Medicare & Medicaid Services
COTS	Commercial Off-the-Shelf
CQL	Clinical Quality Language
CQM	Clinical Quality Measurement
CVD	Cardiovascular Disease
eCQI	Electronic Clinical Quality Information
EHR	Electronic Health Record
FAR	Federal Acquisition Regulation
FFRDC	Federally Funded Research and Development Center
FHIR	Fast Healthcare Interoperability Resources
HDL	High-Density Lipoprotein
HHS	Department of Health and Human Services
HL7	Health Level 7
IT	Information Technology
LDL	Low-Density Lipoprotein
ONC	Office of the National Coordinator for Health Information Technology
PCOR	Patient-Centered Outcomes Research
PCORI	Patient-Centered Outcomes Research Institute
RSAs	Recommendations and Suggested Actions
USPSTF	U.S. Preventive Services Task Force

Reference List

- [1] Osheroff J, Teich J, Middleton B, et al. A Roadmap for National Action on Clinical Decision Support. *J Am Med Inform Assoc*. 2007 Mar-Apr;14(2):141–5. doi: 10.1197/jamia.M2334
- [2] Lloyd-Jones DM, Huffman MD, Karmali KN, et al. Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. *J Am Coll Cardiol*. 2017 Mar 28;69(12):1617-36. doi: 10.1016/j.jacc.2016.10.018.
- [3] Boxwala AA, Rocha HB, Maviglia S, et al. A Multi-Layered Framework for Disseminating Knowledge for Computer-based Decision Support. *J Am Med Inform Assoc* 2011;18 Suppl 1:i132-9. doi:10.1136/amiajnl-2011-000334.
- [4] Tso G, Tu SW, Oshiro C, et al. Automating Guidelines for Clinical Decision Support: Knowledge Engineering and Implementation. *AMIA Annu Symp Proc*. 2017;2016:1189–98. PMID: PMC5333329
- [5] Shiffman RN, Michel G, Essaihi A, Thornquist E. Bridging the Guideline Implementation Gap: A Systematic, Document-Centered Approach to Guideline Implementation. *J Am Med Inform Assoc* 2004;11(5):418-26.

Additional references used during the development of this artifact:

1. DeFelippis AP, Young R. (2016) Estimating Longitudinal Risks and Benefits from Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool. Nov 4, 2016. Accessed on Feb 2, 2017 at: <http://www.acc.org/latest-in-cardiology/articles/2016/11/04/08/56/estimating-longitudinal-risks-and-benefits-from-cv-preventive-therapies>.
2. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, et al. (2013) 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;00:000–000.
3. Goff DC Jr, Lloyd-Jones DM, D’Agostino RB Sr, Gibbons R, Greenland P, et al. (2013) 2013 Report on the Assessment of Cardiovascular Risk: Full Work Group Report Supplement. National Heart, Lung, and Blood Institute.
4. Lloyd-Jones DM, Ning H, Huffman MD, Karmali K, Berendsen M, Goff D. (2016) Final Technical Report: Estimating Benefits in Risk Reduction From Cardiovascular Preventive Therapies in Medicare Patients: Development of the Longitudinal ASCVD Risk Estimator.